We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xceleron Expands Agreement with GlaxoSmithKline
News

Xceleron Expands Agreement with GlaxoSmithKline

Xceleron Expands Agreement with GlaxoSmithKline
News

Xceleron Expands Agreement with GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xceleron Expands Agreement with GlaxoSmithKline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

XCELERON has announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

Clinical studies supported by AMS allow early investigations of the human relevancy of new drugs and novel investigational paradigms greatly enhancing the drug discovery and development process. This second agreement is focused on the rapid analyses and data turnaround for early clinical studies performed by GlaxoSmithKline or its academic and various innovator collaborators. It is complementary to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.

Michael Butler, Ph.D., Chief Executive Officer at Xceleron observed, “We’re just pleased that GlaxoSmithKline recognizes the value of AMS, and Xceleron’s expertise with this ultra-sensitive methodology. We’re now well-positioned to strengthen an already productive collaboration.”
Advertisement